IGF1R and breast carcinoma: As expected, IGF1R deficiency was able to significantly increase breast cancer cell sensitivity to lapatinib in a three-day dose-response assay; however, among the newly identified genes, only TALDO1 depletion conferred similar sensitivity in this assay (Supplementary Fig. 2a–d).